A meta-analysis of icodextrin versus glucose containing peritoneal dialysis in metabolic management of peritoneal dialysis patients

Renal Failure

Volumn 33, Issue 10, 2011, Pages 943-948

  He, Qiang ^a   Zhang, Wei ^a   Chen, Jianghua ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Fasting plasma glucose; Glucose based solutions; Icodextrin based solutions; Meta analysis; Peritoneal dialysis

Indexed keywords

CHOLESTEROL; CREATININE; GLUCOSE; ICODEXTRIN; TRIACYLGLYCEROL; UREA;

ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATININE CLEARANCE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY FAILURE; META ANALYSIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

GLUCANS; GLUCOSE; HEMODIALYSIS SOLUTIONS; HUMANS; PERITONEAL DIALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80054962686     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.615965     Document Type: Article

References (26)

1. Haag-Weber M. Influence of new dialysis solutions on clinical results in patients treated with peritoneal dialysis. Wien Klin Wochenschr. 2005;117(6):89-97. (Pubitemid 43205994)
2. Olszowska A. Glucose polymer in the long dwell exchanges in peritoneal dialysis advantages and limitations. Pol Merkur Lekarski. 2008;24(142):355-358.
3. Lin A, Qian J, Li X, et al. Icodextrin National Multi-center Cooperation Group. Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid. Clin J Am Soc Nephrol. 2009;4(11):1799-1804.
4. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials. 1996;17(1):1-12. (Pubitemid 26120810)
5. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001;323(7303):42-46. (Pubitemid 32682008)
6. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408-412.
7. Konings CJ, Kooman JP, Schonck M, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney Int. 2003;63(4): 1556-1563. (Pubitemid 36350022)
8. Posthuma N, Verbrugh HA, Donker AJ, et al. Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years. Perit Dial Int. 2000;20(2):174-180.
9. Posthuma N, Wee PM, Donker AJ, et al. Serum disaccharides and osmolality in CCPD patients using icodextrin or glucose as daytime dwell. Perit Dial Int. 1997;17(6): 602-607. (Pubitemid 28076107)
10. Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter investigation of Icodextrin in ambulatory peritoneal dialysis. Kidney Int. 1994;46(2):496-503. (Pubitemid 24253059)
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
12. Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol. 2005;16(2):546-554. (Pubitemid 41725153)
13. Plum J, Gentile S, Verger C, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis. 2002;39(4):862-871. (Pubitemid 34263363)
14. Paniagua R, Ventura MD, Avila-Daz M, et al. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int. 2009;29(4):422-432.
15. Opatrnà S. Icodextrine peritoneal dialysis solution in clinical practice. Vnitr Lek. 2008;54(12):1155-1160.
16. Gokal R, Moberly J, Lindholm B, Mujais S. Metabolic and laboratory effects of icodextrin. Kidney Int. 2002;61(81): 62-71.
17. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int. 2001;21(3):275-281. (Pubitemid 32734435)
18. Arima H, Nakamoto H, Okada S, et al. Risk factors for vascular complications in patients on peritoneal dialysis. Adv Perit Dial. 2006;22:192-197.
19. de Moraes TP, Pecoits-Filho R.Metabolic impact of peritoneal dialysis. Contrib Nephrol. 2009;163:117-123.
20. Babazono T, Nakamoto H, Kasai K, et al. Japanese Extraneal Collaborated Study Group. Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am J Nephrol. 2007;27(4):409-415. (Pubitemid 47077205)
21. Iso H, Naito Y, Sato S, et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol. 2001;153(5):490-499. (Pubitemid 32185086)
22. Frampton JE, Plosker GL. Icodextrin: A review of its use in peritoneal dialysis. Drugs. 2003;63(19):2079-2105. (Pubitemid 37229088)
23. Pollock C. Pathogenesis of peritoneal sclerosis. Int J Artif Organs. 2005;28(2):90-96. (Pubitemid 40485206)
24. Gotloib L,Wajsbrot V, Shostak A. Icodextrin induced lipid peroxidation disrupts the mesothelial cell cycle engine. Free Radic Biol Med. 2003;34(4):419-428. (Pubitemid 36140166)
25. Gotloib L. The mesothelium under the siege of dialysis solutions: Old glucose, new glucose, and glucose-free osmotic agents. Adv Perit Dial. 2009;25:6-10.
26. Moriishi M, Kawanishi H. Icodextrin and intraperitoneal inflammation. Perit Dial Int. 2008;3:S96-S100.